Global Influenza Diagnostics Market Size, Share, Growth Analysis, By Test Type(Traditional Diagnostic Test, Molecular Diagnostic Assay), By End-User(Hospital, Laboratories) - Industry Forecast 2022-2028

The Global Influenza Diagnostics Market is segmented based on Test Type, End-User, and Region. Based on Test Type it is categorized into Traditional Diagnostic Test and Molecular Diagnostic Assay. The Traditional Diagnostic Test segment is further bifurcated into RIDT, Viral Culture, Direct Fluorescent Antibody (DFA) Test, and Serological Assay. Molecular Diagnostic Assay is sub-segmented into RT-PCR, Nucleic Acid Sequence-based Amplification (NASBA) Test, Loop-mediated Isothermal Amplification-based Assay (LAMP), Simple Amplification-based Assay (SAMBA), and Other Molecular Diagnostic Assays. By End User, the Influenza Diagnostics Market studied is segmented into hospitals, Laboratories, and Other End Users. Based on the region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Analysis by Test Type

In 2022, the rapid influenza diagnostic test (RIDT) is anticipated to hold the largest market share in the test type segment of the influenza diagnostics market, out of all traditional diagnostic tests. Rapid influenza diagnostic tests (RIDTs) are immunoassays that detect and provide qualitative results for influenza A and B viral nucleoprotein antigens in respiratory specimens. It is capable of diagnosing patients with influenza-like illness, particularly if performed within the first four days of symptoms appearing. RIDT's popularity is driven by the benefits of faster results and ease of use. Some RIDTs are also approved for use in the office or at the patient's bedside. The RIDT segment is also expected to grow rapidly due to its widespread use in point-of-care settings.

Analysis by End-user

The diagnostic laboratories segment dominated the influenza diagnostics market in 2021. The rising prevalence of influenza, as well as the growing demand for rapid disease diagnosis, are driving the growth of this segment

In 2021, North America dominated the influenza diagnostics market and it is expected to maintain its dominance throughout the forecast period (2022-2028). The regional Influenza Diagnostics Market is expected to be driven by the high prevalence of influenza during the forecast period. It is estimated that, approximately 5% to 20% of Americans will be diagnosed with influenza each year in 2022. Moreover, the Centers for Disease Control and Prevention reported 35 million flu-related illnesses, 380,000 flu-related hospitalizations, 20,000 flu-related deaths, and 16 million flu-related medical visits in 2019-2020. This rising disease burden is believed to have a positive impact on market growth in the coming years. RIDTs are widely available all across the region. The short time required to generate results is the reason for the test's wider availability. RIDT can produce results in as little as 15 minutes. With rising influenza-related hospitalizations and pediatric deaths, as well as government organizations' desire to better manage the disease, the North American influenza diagnostics market is expected to expand in the coming years.

Furthermore, the Asia Pacific region is expected to grow at a rapid pace. Adoption of new technology and increased public awareness are expected to be the factors propelling the market growth. Human infection with avian influenza A (H5NI), which resulted in an influenza pandemic, is one of the most concerning aspects of influenza in Asia. There is a growing concern, and countries are actively involved in taking preventive measures to combat the disease's spread.

Driver

• The Human Genome Project and advances in molecular and biomedical technologies have resulted in the development of a plethora of assays and technologies useful for the diagnosis and management of influenza infections. These new technologies, which are based on genomic techniques (such as PCR) and proteomics (such as microarray detection), aid in the discovery of new influenza viruses. They also allow for better surveillance and rapid diagnosis of infectious diseases, which offers a Influenza Diagnostics Market opportunity.
• Geriatrics are vulnerable to a wide range of diseases because their immune systems are weakened, and they are at a high risk of contracting influenza. Individuals with weakened immune systems, such as those suffering from a chronic disease, are also vulnerable to the disease. As a result of an increasing number of people being susceptible to the disease, demand for influenza diagnostics products has increased, fueling the Influenza Diagnostics Market growth.
• The increasing global prevalence of influenza has increased R&D efforts toward effective detection and diagnosis. The majority of research activity is directed toward developing faster and more accurate diagnostic solutions for influenza viruses, which will lead to Influenza Diagnostics Market growth.

Restraint

• The main factors influencing the results of influenza diagnostic tests are sensitivity and specificity. The antigenic variation of influenza viruses is the primary cause of the tests' complexity. As a result, there are variations in the sensitivity and specificity of influenza diagnostic tests, which can affect the final test results. False-negative results are more common than false-positive results as a result of this factor, especially during peak influenza season, which is a factor that restricts the growth of the influenza diagnostics market.

The Influenza Diagnostics Market is highly competitive, with the existence of numerous major firms operating in both domestic and international markets. The industry's top players are embracing strategic collaboration initiatives to improve market share and profitability. Some of the major players in the market are Becton Dickinson, Biomerieux, Merck, and Bio-Rad Laboratories among others who are driving the Influenza Diagnostics Market.

Top Player’s Company Profiles

• Danaher Corporation (US)
• Siemens Healthineers (Germany)
• Thermo Fisher Scientific, Inc. (US)
• F. Hoffmann-LA Roche AG (Switzerland)
• Abbott Laboratories, Inc. (US)
• Hologic, Inc. (US)
• BioMérieux SA (France)
• Quidel Corporation (US)
• Becton, Dickinson, and Company (US)
• Meridian Bioscience (US)
• GenMark Diagnostics, Inc. (US)
• Luminex Corporation (US)
• Tecan Trading AG (Switzerland)
• DiaSorin SA (Italy)
• Altona Diagnostics GmbH (Germany)

Recent Developments

• In May 2022, The American pharmaceutical company announced that it has obtained Nod from the USFDA for the drug Aptima CMV Quant Assay for human cytomegalovirus. Use. And this could be a great development in reducing the adverse effect of the virus on humans.
• In February 2022, Siemens Healthineers, in partnership with United Nations Children's Fund, today announced its contribution to strengthening health systems in the various African region by improving access to diagnostics and the link to treatment of major diseases.
• In September 2021, Simplexa COVID-19 & Flu A/B Direct kit from DiaSorin Molecular LLC received the CE mark. The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, and influenza B virus from the same patient sample in a single reaction well.

• Vaccination is a major method of immunizing individuals against infectious diseases to avoid serious complications, particularly in immunocompromised patients who are at high risk. Mutation of the virus serotype proves to be a major impediment because vaccination becomes difficult in such cases, putting the individual at risk of contracting the virus. Thus, as virus types change, it is critical to detect their presence in patients and administer timely medication to prevent fatalities. As a result, the demand for influenza diagnostics products has increased, accelerating market growth.
• The rising geriatric population, broadening government anti-influenza initiatives, rising prevalence of chronic diseases such as diabetes, heart and blood disorders, and the emergence of technologically advanced influenza diagnostic tests are some of the key factors driving the influenza diagnostics market's growth.
• Pregnant women, children, the elderly, immunocompromised patients with chronic medical conditions, and healthcare workers are at high risk of contracting influenza. The treatment for influenza consists of a variety of antiviral drugs that help to reduce complications and fatalities such as death. Antiviral drugs used conventionally are ineffective in the majority of patients due to drug resistance. As a result, the development of vaccines and drugs has seen an increase in demand, assisting developers in the industry.

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.

According to our analysis, the increasing prevalence of influenza and related chronic diseases, increased research and development activities in influenza diagnostics technologies, growing awareness for early detection using specific diagnostic tests, and other factors are driving the Global Influenza Diagnostics Market. However, the rising cost of influenza diagnostic kits and reagents is the primary impediment to Influenza Diagnostics Market growth. Furthermore, variability in sensitivity and specificity among influenza diagnostic tests, as well as the presence of a complex regulatory framework for the approval of new diagnostic tests, are expected to limit market growth to some extent.